John M. Fevig
Bristol-Myers Squibb (United States)(US)Discovery Laboratories (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Synthesis and Catalytic Reactions, Peptidase Inhibition and Analysis, Chemical synthesis and alkaloids, Chemical Synthesis and Analysis
Most-Cited Works
- → Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa(2001)172 cited
- → Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants(2003)96 cited
- → Synthesis applications of cationic aza-Cope rearrangements. 24. The aza-Cope-Mannich approach to Strychnos alkaloids. Short stereocontrolled total syntheses of (.+-.)-dehydrotubifoline and (.+-.)-akuammicine(1993)86 cited
- → New approach to Strychnos alkaloids. Stereocontrolled total synthesis of (.+-.)-dehydrotubifoline(1991)70 cited
- → Chapter 9. Anticoagulants: Thrombin and Factor Xa Inhibitors(1999)57 cited
- → Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa(2006)53 cited